TNFSF13 and lupus nephritis: The most striking finding of our study is that despite having more severe baseline disease activity and more aggressive lupus nephritis, patients in the BAFF/APRIL-guided telitacicept group achieved comparable or better clinical responses than those in the conventional belimumab group.